Yildirim Rahsan, Gundogdu Mehmet, Ozbıcer Aysu, Kiki Ilhami, Erdem Fuat, Dogan Hasan
Department of Hematology, Medical School, Ataturk University, Erzurum, Turkey.
Transfus Apher Sci. 2013 Feb;48(1):45-9. doi: 10.1016/j.transci.2012.06.015. Epub 2012 Aug 11.
Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia (AML) and has distinct hematopathologic, cytogenetic, clinical and molecular features. This study was a retrospective review of 18 adult patients (10 male, 8 female; mean age of 32.17 ± 5.66 (15-61 years) with APL at our department from January 2006 to December 2011. Following induction therapy, 17 patients achieved CR, 1 of 18 patients died of result bleeding within thirty-sixth hours of admission. In two of 18 patients developed RAS. The relapse rate was 27% (5/18). Fourteen of 18 patients (77%) have been followed in remission. APL is a malignancy requiring quick diagnosis, efficient treatment and supportive care system. ATO, one of the important therapy option in the treatment of APL, cannot be obtained easily in developing countries. This may lead to an increase in the mortality rates. The studies should be made with more number of patients and a longer period of time for accurate results.
急性早幼粒细胞白血病（APL）是急性髓系白血病（AML）的一种特殊类型，具有独特的血液病理学、细胞遗传学、临床和分子特征。本研究回顾性分析了2006年1月至2011年12月期间在我科就诊的18例成年APL患者（男10例，女8例；平均年龄32.17±5.66岁（15 - 61岁））。诱导治疗后，17例患者达到完全缓解（CR），18例患者中有1例在入院后36小时内死于颅内出血。18例患者中有2例发生了RAS。复发率为27%（5/18）。18例患者中有14例（77%）在缓解期接受了随访。APL是一种需要快速诊断、有效治疗和支持性护理系统的恶性肿瘤。三氧化二砷（ATO）是治疗APL的重要治疗选择之一，在发展中国家不易获得。这可能导致死亡率上升。应该对更多患者进行更长时间的研究以获得准确结果。
